As the FDA wavers from cuts, changes and departures under the second Trump administration, another vital figure of the agency ...

BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at ...

BEIJING, CHINA / / March 31, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing ...

The FDA is poised to issue a final decision on the approval and marketing of Yutrepia, an inhaled dry powder formulation of ...

All three companies are early-stage biotechnology companies working on next-generation therapeutics with advanced ...

The pharma and biotech sector has been under pressure since Donald Trump returned to the White House earlier this year ...

As director of the FDA's Center for Biologics Evaluation and Research, Marks has publicly supported programs that expedited ...

Strengthened the cash balance to provide runway into 2027, allowing Allarity to accelerate stenoparib's clinical development, ...

Below is a press release by The City of Goleta regarding an upcoming DUI Checkpoint on Saturday April 5th, 2025 from 6:00pm - ...

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

By Manas Mishra (Reuters) -Shares of U.S. drugmakers fell before the bell on Monday after reports that the Food and Drug ...